Digital Biomanufacturing Market Report 2026

The digital biomanufacturing market size has grown rapidly in recent years. It will grow from $23.97 billion in 2025 to $27.25 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to growth of biologics production, need for process efficiency, adoption of automation in pharma manufacturing, regulatory focus on quality compliance, increasing manufacturing complexity.

The digital biomanufacturing market size is expected to see rapid growth in the next few years. It will grow to $46.02 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to expansion of cell and gene therapies, adoption of continuous manufacturing, integration of AI in bioprocessing, demand for faster time to market, investment in smart biomanufacturing facilities. Major trends in the forecast period include data driven bioprocess optimization, automation of biomanufacturing operations, digital twin adoption, real time process monitoring, AI enabled quality control.

The expanding pharmaceutical industry is expected to drive growth in the digital biomanufacturing market. The pharmaceutical sector, involved in the research, development, and production of medicines, is experiencing growth due to rising global demand for healthcare and medications, driven by an increasing and aging population. Digital biomanufacturing supports this industry by integrating advanced data analytics, automation, and real-time monitoring to optimize drug production, enhance quality control, reduce manufacturing costs, and accelerate the development of safe and effective therapies. For example, in 2024, North America accounted for 54.8% of global pharmaceutical sales, while Europe represented 22.7%, with an estimated €55 billion invested in R&D in Europe, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA). Therefore, the growth of the pharmaceutical industry is propelling the digital biomanufacturing market.

Key players in the digital biomanufacturing market are focusing on innovative technologies such as single-use bioreactors to improve process efficiency, scalability, and flexibility in biologics production. Single-use bioreactors eliminate the need for cleaning and sterilization between batches, reduce contamination risks, and streamline the production of biologics and vaccines. For instance, in March 2025, the European Commission launched the Biotech and Biomanufacturing Hub, an online platform supporting biotech and biomanufacturing companies across the EU, particularly startups and SMEs. The hub provides access to funding programs, regulatory guidance, intellectual property support, pilot and testing infrastructure, and networking tools, forming a key part of the Commission’s strategy to boost Europe’s biotech ecosystem, enhance competitiveness, and reduce dependency on external supply chains.

In December 2023, Danaher Corporation, a U.S.-based science and technology company, acquired Abcam plc, a UK-based biotechnology and life sciences firm, for an undisclosed amount. This acquisition strengthens Danaher’s life sciences portfolio by integrating Abcam’s expertise in high-quality antibodies and reagents, enhancing research and diagnostic capabilities, and expanding global reach in the biotechnology and pharmaceutical sectors.

Major companies operating in the digital biomanufacturing market are Sanofi SA; Thermo Fisher Scientific Inc.; Honeywell International Inc.; SAP SE; Danaher Corporation; ABB AG; Siemens Healthineers AG; Emerson Electric Co; GE HealthCare Technologies Inc.; Atos SE; Agilent Technologies Inc.; Cytiva Europe GmbH; Lonza Group AG; Dassault Systèmes SE; Sartorius AG; Pall Corporation; Eppendorf AG; Symphony Innovation LLC; Koch Membrane Systems Inc.; Culture Biosciences Inc.; Bota Biosciences Inc.; Shimadzu Corporation; e-MSion; Immersciobio GmbH.

North America was the largest region in the digital biomanufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global digital biomanufacturing market during the forecast period. The regions covered in the digital biomanufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital biomanufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the digital biomanufacturing market by increasing costs of imported bioreactors, sensors, automation equipment, and advanced control systems. These higher costs have affected biopharmaceutical manufacturers, particularly in asia pacific and emerging markets. Capital intensive digital upgrades have been delayed due to increased equipment expenses. Companies are responding by prioritizing software driven optimization and analytics solutions. Tariffs have also supported local manufacturing of bioprocess equipment and strengthened regional life sciences supply chains.

The digital biomanufacturing market research report is one of a series of new reports that provides digital biomanufacturing market statistics, including digital biomanufacturing industry global market size, regional shares, competitors with a digital biomanufacturing market share, detailed digital biomanufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the digital biomanufacturing industry. This digital biomanufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital biomanufacturing leverages digital technologies to enhance efficiency and innovation in biomanufacturing processes.

Digital biomanufacturing encompasses various types of technologies aimed at improving manufacturing quality, productivity, and practices in the production of biological products. These technologies, including AI, IoMT solutions, process analytical tools, data analytics software, and digital twin technologies, are utilized to optimize bioprocesses, automate manufacturing, and enhance control. Biopharmaceutical companies, academic institutions, and research institutes leverage these advancements to produce antibodies, cell and gene therapies, proteins, vaccines, and other biologics with improved efficiency, product quality, and scalability.

The digital biomanufacturing market consists of revenues earned by entities by providing various technologies that support the manufacturing of biologics such as big data, cloud computing, lean product and process development, sensor technologies, process control, and enterprise control. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital biomanufacturing market also includes sales of sensors, analyzers, and actuators and process control systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.